There were no statistically significant differences in age, body mass index (BMI), PSA levels, high blood pressure (HBP), diabetes mellitus (DM), smoking history, Gleason score, pre-enrollment abiraterone duration, pre-enrollment enzalutamide duration, or extent of disease (EOD) score between the DP+MDV 3100 and DP groups before treatment (P > 0.05), as shown in Table 1. This evidence concerns the gene KLK3 and diabetes mellitus.